搜尋結果
- Mirror 相關文章 - 雅虎香港
2024年7月11日 · 1. About lecanemab (LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).
2023年11月20日 · Eisai serves as the lead of LEQEMBI development and regulatory submissions globally, with both Eisai and Biogen Inc. (U.S.) co-commercializing and co-promoting the product. Eisai has the final decision-making authority. Please see full Prescribing Information, including Boxed WARNING in the United States.
2022年11月30日 · Eisai’s Clarity AD was a global confirmatory Phase 3 placebo-controlled, double-blind, parallel-group, randomized study in 1,795 people with early AD (lecanemab group: 898 placebo group: 897) at 235 sites in North America, Europe, and Asia.
2024年6月28日 · China is the third country to launch LEQEMBI following the United States and Japan. LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques in AD, thereby reducing both Aβ protofibrils and Aβ plaques in the brain.
2024年7月23日 · Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest findings on its Alzheimer’s disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) protofibril* antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI ®), at the Alzhe...
2022年3月22日 · Four key symposium presentations explored how lecanemab’s clinical efficacy data, overall amyloid-related imaging abnormality (ARIA) rates, biomarker relationships to clinical outcomes, potential dosing regimens, and administration have the potential to benefit people living with early AD.
2024年8月6日 · August 6, 2024. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) reconfirmed today that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI ® (generic name: lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.